Good news for ICUs and patients
The Intensive Care Platform Trial - INCEPT - was approved by the regulators
INCEPT is a very broad domain based, adaptive platform trial assessing everyday interventions in ICUs
1. enrolled in first domain (albumin use vs no use in shock) in april 2025
https://incept.dk/
The Intensive Care Platform Trial - INCEPT - was approved by the regulators
INCEPT is a very broad domain based, adaptive platform trial assessing everyday interventions in ICUs
1. enrolled in first domain (albumin use vs no use in shock) in april 2025
https://incept.dk/
Comments
-Dosing strategies for prophylactic LMWH (low vs. intermediate vs. weight-based)
-Continuos glucose monitoring (CGM) vs. usual care in pts on insulin
-Management of atrial fibrillation (amiodaron vs. digoxin vs. beta-blocker (likely))
And more in development
And with clinicians, patients, relatives (read our COS)
Funded by @novo-nordisk.bsky.social Sygeforsikringen Danmark and others
https://journals.lww.com/ccmjournal/abstract/9900/a_core_outcome_set_for_adult_general_icu_patients.439.aspx